Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 11/20 | 0.64 |
| ▸ | SRD5A2 | P31213 | 9/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.64 |
| ▸ | HSD3B1 | P14060 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | THPO | P40225 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13495829 | 1.00 | SRD5A1 (0.64) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL16488278 | 1.00 | SRD5A1 (0.64) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL4266160 | 0.86 | SRD5A1 (0.66) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL4266165 | 0.86 | SRD5A1 (0.66) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL25247958 | 0.86 | SRD5A1 (0.62) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL13848517 | 0.84 | SRD5A1 (0.60) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8679765 | 0.84 | SRD5A1 (0.62) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8157337 | 0.84 | SRD5A1 (0.60) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8536922 | 0.84 | SRD5A1 (0.60) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8679763 | 0.84 | SRD5A1 (0.62) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7446110-B2 | 17-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators | MERCK & CO., INC. (US) | 2008-11-04 | — | — | US | disclosed |
| US-20070054933-A1 | 17-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators | MERCK & CO., INC (US) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054933-A1 | 17-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators | AR, SHBG, NR5A1 | SRD5A1 18/4885SRD5A2 21/4885LMNA 2668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.